Operation Diabetes: Optimizing Use of GLP-1 Receptor Agonists - Operation Game 


Release Date: May 15, 2020
Last Reviewed: May 7, 2020
Expiration Date: May 15, 2021
Time to Complete Activity:  0.5 hour 


Faculty
Vivian Fonseca, MD

Professor of Medicine and Pharmacology
Tullis Tulane Alumni Chair in Diabetes
Chief, Section of Endocrinology
Tulane University Health Sciences Center
New Orleans, LA

Javier Morales, MD, FACP, FACE
Associate Clinical Professor of Medicine
Donald and Barbara Zucker School of Medicine at Hofstra Northwell
Vice President, Advanced Internal Medicine Group, PC
East Hills, NY

Debbie A. Hinnen, APN, BC-ADM, CDE, FAAN, FAADE 
Advanced Practice Nurse and Certified Diabetes Educator 
University of Colorado Health
Colorado Springs, CO
Adjunct Faculty, Graduate Nursing Department
Wichita State University
Wichita, KS
This activity is provided by Paradigm Medical Communications, LLC.   

Target Audience
This activity has been designed to address the educational needs of primary care clinicians. It may also be of benefit to other healthcare professionals who manage patients with diabetes using glucagon-like peptide-1 (GLP-1) receptor agonists. 

Statement of Need
The incidence of diabetes, particularly type 2 diabetes (T2D), is increasing, and with this increase comes an associated rise in diabetes complications and comorbidities such as obesity, cardiovascular disease (CVD), and renal disease. There are several classes of agents to treat hyperglycemia from which clinicians can choose. In recent years, data on GLP-1 receptor agonists have emerged demonstrating beneficial extraglycemic effects, yet the level of benefit varies among different members of the class. Most recent guideline recommendations include preferences for GLP-1 receptor agonists to individualize therapy for patients with diabetes and CVD. Despite these benefits, the uptake of and adherence to GLP-1 receptor agonist therapy is low. Because the majority of T2D management occurs in the primary care setting, primary care providers play a crucial role in optimizing T2D therapy. However, primary care providers are challenged to remain abreast of the latest data on GLP-1 receptor agonists, the clinical distinctions between class members, managing side effects, and strategies for patient education about GLP-1 receptor agonists and how to increase adherence to therapy.

Learning Objectives
Upon proper completion of this activity, participants should be better able to:
  • Select treatment for patients who have diabetes based on the extraglycemic effects of GLP-1 receptor agonists
  • Formulate management strategies to relieve common adverse events associated with GLP-1 receptor agonist therapy
  • Outline key elements of GLP-1 receptor agonist therapy to include in patient education
Physician Accreditation Statement
Paradigm Medical Communications, LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Physician Credit Designation Statement
Paradigm Medical Communications, LLC designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. 

PA Continuing Education
PAs may claim a maximum of 0.5 Category 1 credits for completing this activity. NCCPA accepts AMA PRA Category 1 Credit™ from organizations accredited by ACCME or a recognized state medical society.

Nurse Practitioner Continuing Education
The American Academy of Nurse Practitioners Certification Program (AANPCP) accepts certificates of participation for educational activities certified for AMA PRA Category 1 Credit™ from organizations accredited by the ACCME.  Individuals are responsible for checking with the AANPCP for further guidelines.

This activity is supported by an educational grant from Novo Nordisk Inc.   

Instructions for Participation   
To receive a CME certificate of participation, you should:
  • Follow instructions to register or log in with your professional information and complete the preactivity assessment
  • View the online activity in its entirety
  • Complete and submit the online posttest and evaluation
A certificate of participation will be available for download/printing immediately following your successful completion of the posttest and evaluation.

For questions regarding CME credit, contact the Paradigm CME Department at (845) 398-5949.

There is no fee required for participation in this activity.

Hardware/Software Requirements
This certified CME activity is designed using HTML5 video. 

Supported Browsers:
For Desktops (Windows/Mac)
Microsoft Edge 40 or higher, Firefox 28 or higher, Safari 5.1 or higher, Google Chrome 31 or higher, Opera 21 or higher

For Tablets (iPad/Android/Surface)
iOS Safari 4 or higher, Android 2.3 or higher, IE Mobile 10 or higher

Adobe Reader 
This activity is in Adobe Acrobat PDF format. To view the activity, you will need Adobe Reader. If you do not have Adobe Reader installed on your computer, please visit http://get.adobe.com/reader/ to install a free version of Adobe Reader.

Technical Support: If you have any technical problems or playback issues, email us at contactus@paradigmmc.com.

Disclosures
In accordance with ACCME requirements on disclosure, faculty and contributors are asked to disclose any relationships with commercial interests associated with the area of medicine featured in the activity. These relationships are described below.

Vivian Fonseca, MD
Consulting Fees: Abbott Laboratories; Asahi Kasea Pharma Corporation; AstraZeneca; Eli Lilly and Company; Intarcia Therapeutics; Novo Nordisk Inc.; sanofi-aventis U.S. LLC; Takeda Pharmaceutical Company
Grant/Research Support: Bayer Pharmaceuticals; Boehringer Ingelheim Pharmaceuticals, Inc
Ownership interest: Amgen; BRAVE4Health; Insulin Algorithms; Microbiome Technologies

Javier Morales, MD, FACP, FACE
Consulting Fees: Boehringer Ingelheim Pharmaceuticals, Inc; Eli Lilly and Company; Intarcia Therapeutics; Novo Nordisk Inc.
Speakers Bureau: AstraZeneca; Boehringer Ingelheim Pharmaceuticals, Inc; Eli Lilly and Company; Novo Nordisk Inc.

Debbie A. Hinnen, APN, BC-ADM, CDE, FAAN, FAADE
Consulting Fees: Eli Lilly and Company; Janssen Pharmaceuticals; Novo Nordisk Inc.; sanofi-aventis U.S. LLC 
Speakers Bureau: Eli Lilly and Company; Janssen Pharmaceuticals; Novo Nordisk Inc.; sanofi-aventis U.S. LLC

Paradigm Medical Communications, LLC staff members have no financial relationships to disclose.

Independent peer, resident/fellow, and patient reviewers  have no financial relationships to disclose.

Resolution of Conflict of Interest
Paradigm Medical Communications, LLC has implemented a system to resolve conflicts of interest for each CME activity to help ensure content is objective, fair and balanced, independent, and aligned with the public interest. Conflicts, if any, are resolved through one or more processes. All CME content in this activity was independently reviewed to ensure that it is free of commercial bias, scientifically rigorous, aligned with the public interest, and compliant with all regulatory guidance and the ACCME’s Standards for Commercial Support of Continuing Medical Education.

Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not approved by the FDA.

Disclaimer
This CME activity represents the views and opinions of the individual faculty, and does not constitute the opinion or endorsement of, or promotion by, Paradigm Medical Communications, LLC. Reasonable efforts have been taken to present educational subject matter in a balanced, unbiased fashion, and in compliance with regulatory requirements. However, each activity participant must always use his or her own personal and professional judgment when considering further application of this information, particularly as it may relate to patient diagnostic or treatment decisions including, without limitation, FDA-approved uses and any off-label uses.

If included, signed statements of informed consent granting permission for publication have been obtained for all photographs and videos in which an individual can be identified.

As an ACCME-accredited provider, Paradigm Medical Communications, LLC’s activities must include a balanced view of therapeutic options. Use of generic names contributes to this impartiality. The use of trade names should not be viewed as an endorsement of specific products by Paradigm Medical Communications, LLC.

Terms of Use and Privacy Policy
Disclaimer
The materials provided for this activity are for informational purposes only, and should not be used for diagnosis or treatment of a health problem without consulting a licensed medical professional. This CME activity represents the views and opinions of the individual faculty, and does not constitute the opinion or endorsement of, or promotion by, Paradigm Medical Communications, LLC. References to any entity, product, service, or source of information on this website should not be considered an endorsement, either direct or implied, by Paradigm Medical Communications, LLC. Paradigm Medical Communications, LLC accepts no liability for the content referenced in this activity.

Privacy policy
Paradigm Medical Communications, LLC or hosted contracted partner is committed to protecting the privacy of those who participate in the activities located at www.paradigmmc.com (herein referred to as “website”). The information below describes the security of the website for safeguarding personal information and the rationale for collection and use of personal information.

Security/safeguarding personal information
This website has physical and procedural safeguards in place to prevent unauthorized access to personal information used to access this website.

Collection and use of your personal information
The submission of certain personally identifiable information is necessary to award and track the credits participants may earn after completing the program. Required items include first name, last name, degree, and email address. These items are necessary. Participants are also required to complete an evaluation of the CME activity. All evaluative information submitted is collected and retained, and used by Paradigm Medical Communications, LLC to continuously improve the learning experience.

Paradigm Medical Communications, LLC does not transfer, sell, or share personal information with outside parties. Paradigm Medical Communications, LLC will not otherwise disclose personal information unless required to in a legal process. Paradigm Medical Communications, LLC staff members review individual test results to the extent necessary to record and track participants’ credits.

Contact Us
If you have any questions or comments, please email us at contactus@paradigmmc.com

© 2020 Paradigm Medical Communications, LLC except where noted. Content may not be reproduced in whole or part without the express written permission of Paradigm Medical Communications, LLC.